Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment-Reference-Cited by-同舟云学术

Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment

Published:2016-05-29 Issue:3 Volume:82 Page:728-738
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Gupta Neeraj¹,Hanley Michael J.¹,Venkatakrishnan Karthik¹,Perez Raymond²,Norris Robin E.³,Nemunaitis John⁴,Yang Huyuan¹,Qian Mark G.¹,Falchook Gerald⁵,Labotka Richard¹,Fu Siqing⁶

Affiliation:

1. Millennium Pharmaceuticals, Inc. Cambridge MA USA

2. University of Kansas Clinical Research Center Fairway KS USA

3. University Hospitals of Cleveland Cleveland OH USA

4. Mary Crowley Cancer Research Centers Dallas TX USA

5. Sarah Cannon Research Institute at HealthONE Denver CO USA

6. The University of Texas MD Anderson Cancer Center Houston TX USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.12991

Reference27 articles.

1. NINLARO® (ixazomib) capsules for oral use. United States Prescribing Information 2015. Millennium Pharmaceuticals Inc. Cambridge MA USA [online]. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208462lbl.pdf(last accessed 19 January 2016).

2. Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma

3. Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies

4. Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis

5. A drug–drug interaction study between the strong CYP3A4 inhibitor ketoconazole (keto) and ixazomib citrate (MLN9708), an investigational, orally active proteasome inhibitor, in patients with advanced solid tumors or lymphoma;Gupta N;J Clin Oncol,2013

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combined green analytical principles and quality by design for ultraperformance liquid chromatography analytical method development, the characterization and in-silico toxicity prediction of Ixazomib degradation products using mass spectrometry;Green Analytical Chemistry;2024-03

2. Proteasome inhibition in combination with immunotherapies: State-of-the-Art in multiple myeloma;Blood Reviews;2023-09

3. Discovery of a Novel Ubenimex Derivative as a First-in-Class Dual CD13/Proteasome Inhibitor for the Treatment of Cancer;Molecules;2023-08-30

4. Organoboronic acids/esters as effective drug and prodrug candidates in cancer treatments: challenge and hope;Journal of Enzyme Inhibition and Medicinal Chemistry;2023-06-15

5. Dose Titration of Ixazomib Maintenance Therapy in Transplant‐Ineligible Multiple Myeloma: Exposure–Response Analysis of the TOURMALINE‐MM4 Study;Clinical Pharmacology & Therapeutics;2023-05-23